This trial is testing if Avastin can help to control ovarian, fallopian, or primary peritoneal cancer after it has been found during second-look surgery.
- Ovarian Cancer
- Primary Peritoneal Cancer
- Cervical Cancer
1 Primary · 0 Secondary · Reporting Duration: 63 days
Side Effects for
Awards & Highlights
1 Treatment Group
1 of 1
35 Total Participants · 1 Treatment Group
Primary Treatment: Bevacizumab · No Placebo Group · Phase 2
Who is running the clinical trial?
Age 18+ · Female Participants · 1 Total Inclusion CriteriaMark “Yes” if the following statements are true for you:
Frequently Asked Questions
How many participants are being admitted to this clinical trial?
"Affirmative. Clinicaltrials.gov data confirms that this clinical trial is actively enrolling, with the first posting having been on November 1st 2016 and the most recent edit being made on January 3rd 2022. The study has need for 35 patients at a single medical centre." - Anonymous Online Contributor
Has Bevacizumab been granted authorization from the FDA?
"Evidence concerning the safety of Bevacizumab is limited to Phase 2 trials, so it received a score of two. No data exists that confirms its efficacy yet." - Anonymous Online Contributor
For what diseases and ailments is Bevacizumab commonly prescribed?
"Bevacizumab can be employed to combat malignant neoplasms, recurrent platinum-sensitive primary peritoneal cancer, and Stage IV epithelial ovarian cancer post-surgical excision." - Anonymous Online Contributor
Could you please provide a compendium of research regarding Bevacizumab?
"Presently, there are 355 clinical trials involving Bevacizumab with 89 of those studies being in Phase 3. Of the 17017 sites researching this medication, many reside in Taibei, Taiwan." - Anonymous Online Contributor
Are researchers currently recruiting participants for this investigation?
"The clinicaltrials.gov webpage indicates that this medical trial is currently accepting applicants, having opened on the 1st of November 2016 and been updated most recently on 3rd January 2022." - Anonymous Online Contributor